The National Institutes of Health on Wednesday detailed how its researchers and collaborators developed a treatment for infants with Niemann-Pick Type C disease that has won U.S. Food and Drug Administration approval. The drug, cyclodextrin, sold as Adrabetadex, extended survival in participants with the rare pediatric neurodegenerative disorder in a large, international clinical trial, NIH said.

NIH said FDA approved the drug on Nov. 17, 2026. According to the institute, the effort represents foundational research that began 20 years ago and involved Beren Therapeutics of Thousand Oaks, California. NIH Director Jay Bhattacharya, M.D., Ph.D., said “there was no shortcut” for a disease this complex.

Niemann-Pick Type C stems from mutations in the NPC1 gene, NIH said. The mutations reduce a protein that helps move lipids and cholesterol through cells, causing abnormal buildup. Without this transport, patients face progressive neurological decline and early death, according to the institute.

Severity varies, but half of cases are identified before age 10, NIH said. Cases found before age 2 have the worst outcomes. Children may first show delays in reaching normal developmental milestones and later develop cognitive decline similar to dementia, according to the institute.

NIH traced the drug’s path to a natural history trial launched in 2006 under its Bench-to-Bedside program. From there, Forbes D. Porter, M.D., Ph.D., obtained an Investigational New Drug authorization from FDA to start an early-phase trial at the NIH Clinical Center. “Giving families more time together” reflects the work’s aim, Porter said.

In 2016, NIH said a cooperative research and development agreement supported multisite, multinational late-phase trials. Those trials showed positive biomarker data but did not meet clinical outcome measures needed for approval, the institute said. Subsequent survival analyses with Beren Therapeutics and Dr. Elizabeth Berry-Kravis at Rush University Medical Center found increased survival in infantile-onset disease, which NIH said led to FDA approval. The institute said data from its natural history and therapeutic studies were critical to the analysis.

John Gaitanis, M.D., director of NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development, said he was proud of NIH’s role in creating the first FDA-approved treatment for infants with the disease. NIH said it remains committed to research in rare diseases.